Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1244880

NCCc1cccc(C(=O)Nc2ccc(Nc3nccc(-c4cccc5c4oc4ccccc45)n3)cc2)c1.O=C(O)C(F)(F)F

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 4/20 0.41
JAK2 O60674 3/20 0.41
CCNT1 O60563 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CDK9 P50750 1/20 0.39
CCNA1 P78396 1/20 0.39
ABL1 P00519 4/20 0.39
PDGFRA P16234 4/20 0.39
SRC P12931 3/20 0.39
PDGFRB P09619 3/20 0.39
BCR P11274 2/20 0.39
PRKCA P17252 2/20 0.39
PRKD3 O94806 1/20 0.39
PRKCG P05129 1/20 0.39
PRKCB P05771 1/20 0.39
PRKCH P24723 1/20 0.39
PRKCI P41743 1/20 0.39
PRKCE Q02156 1/20 0.39
PRKCQ Q04759 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4384220 0.86 PIP4K2C (0.39) AURKAABL1BCREGFR
SCHEMBL1244770 0.80 PIP4K2C (0.43) AURKACCNT1CDK9ABL1BCR
Trifluoroacetic Acid SCHEMBL1243561 0.80 LOXL2 (0.41) AURKAABL1BCREGFR
Trifluoroacetic Acid SCHEMBL1242002 0.79 PIP4K2C (0.43) AURKAABL1BCREGFR
Trifluoroacetic Acid SCHEMBL1243718 0.79 ABL1 (0.47) JAK2CCNT1CCNA2CDK2CDK9
Trifluoroacetic Acid SCHEMBL1244801 0.76 PIP4K2C (0.39) AURKAABL1BCRKDRTEK
Trifluoroacetic Acid SCHEMBL1244312 0.75 PIP4K2C (0.45) AURKAABL1BCREGFRF2
Trifluoroacetic Acid SCHEMBL1242277 0.75 PIP4K2C (0.43) AURKACCNT1CCNA2CDK2CDK9
SCHEMBL1241964 0.75 ABL1 (0.40) AURKAJAK2CCNT1CCNA2CDK2
Trifluoroacetic Acid SCHEMBL1244417 0.74 PIP4K2C (0.46) CCNT1CCNA2CDK2CDK9CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879853-B2 tyrosisne kinase inhibitors such as N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-morpholin-4-yl-benzamide, used as anticasrcinogenic or antoproliferative agents, especially in the treatment of breast cancer BAYER SCHERING PHARMA AG (DE) 2011-02-01 US disclosed
US-20070208034-A1 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors ATLANTA PHARMA AG (DE) 2007-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208034-A1 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors CDK2, DCK, DTYMK AURKA 222/4885JAK2 399/4885CCNT1 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.